Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Thursday, 16 February 2017

Active Biotech AB Year-end report January - December 2016

Active Biotech    

Published: 08:30 CET 16-02-2017 /GlobeNewswire /Source: Active Biotech / : ACTI /ISIN: SE0001137985

Active Biotech AB Year-end report January - December 2016

 

 

Laquinimod

  • The clinical trials CONCERTO, ARPEGGIO and LEGATO-HD are progressing according to plan
  • The study results from the pivotal clinical Phase 3 CONCERTO trial in relapsing remitting multiple sclerosis (RRMS) are expected in the first half of 2017
  • The study results from the clinical Phase 2 ARPEGGIO trial, evaluating laquinimod for the treatment of primary progressive multiple sclerosis (PPMS), are expected in the second half of 2017
  • Orphan Drug Designation granted in the US by the FDA ("US Food and Drug Administration")  for laquinimod for the treatment of Huntington's disease

 

ANYARA     

  • A licensing agreement has been entered into with NeoTX Therapeutics Ltd

 

Tasquinimod, Paquinimod and SILC

  • Out-licensing activities are continuing
  • The European Patent Office has granted a patent application covering tasquinimod for use in the treatment of multiple myeloma
  • Product patent for SILC substances granted by the European Patent Office

 

New share issue 

  • Rights issue implemented in fourth quarter generating proceeds of SEK 53.7 M for the company after issue expenses

 

Financial summary

SEK M

Oct - Dec

  Jan - Dec

 

2016

2015

2016

2015

Net sales

7.1

5.0

19.0

16.3

Operating loss

-13.5

-28.2

-55.1

-177.9

Loss for the period

-14.8

-40.8

-59.6

-193.5

Loss per share, before and after dilution (SEK)

-0.16

-0.45

-0.65

-2.13

Cash and cash equivalents

 

 

77.7

103.6

 

 

 

 

 

 

  • Operating costs for full-year 2016 reduced by 62% (SEK 120.1 M) compared with 2015
     
  • Operations are progressing according to plan pending the Phase 3 results for laquinimod in the first half of 2017

 

For further information, please contact:     

 

  Tomas Leanderson, President and CEO

  Tel: +46 (0) 46 19 20 95

 

  Hans Kolam, CFO

  Tel: +46 (0)46 19 20 44

 

Active Biotech AB

(Corp. Reg. No. 556223-9227)

Box 724, SE-220 07 Lund

Tel: +46 (0)46-19 20 00

   

The report is also available at www.activebiotech.com.



Active Biotech AB Year-end report January – December 2016



This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of NASDAQ OMX Corporate Solutions clients. Source: Active Biotech, Scheelevägen 22
Box 724, LUND 220 07,
If you would like to unsubscribe and stop receiving these e-mails click here.